SRPT · Sarepta Therapeutics, Inc.
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-05 |
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and |
| 2026-07-29 |
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 29, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta’s 2024 Employment Commencement |
| 2026-07-27 |
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
– Severino joins Sarepta’s Board of Directors – Doug Ingram to retire from Sarepta CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 27, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as |
| 2026-07-22 |
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 22, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. |
| 2026-06-30 |
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 30, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 |
| 2026-06-30 |
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
– Accepted for review with target action date of February 28, 2027 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 30, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted |
| 2026-06-01 |
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47 th Annual Global |
| 2026-05-13 |
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 13, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the |
| 2026-05-06 |
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026, |
| 2026-04-22 |
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 22, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. |
| 2026-03-31 |
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s |
| 2026-03-25 |
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 Company to host investor call on March 25, 2026, at 8:30 a.m. Eastern time CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. |
| 2026-03-24 |
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 24, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early |
| 2026-03-19 |
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
– Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to traditional approval CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 19, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic |